Obesity Featured Articles

  1. Early Access Program In France: How Much Of An Opportunity Is It? 6/12/2025

    Navigating France’s Early Access Program is more complex than ever. Amid declining approval rates and mandatory data collection, here’s what pharmaceutical companies need to know about the changing landscape.

  2. Insights From Pharma 2025: The Impact Of The European Health Data Space (EHDS) Reform On Healthcare Systems 6/12/2025

    Experts explore the revolutionary European Health Data Space, a reform designed to enhance patient data control, streamline care across borders, and unlock new opportunities for medical research.

  3. Insights From Pharma 2025: Driving Commercial Success In Pharma: The Role Of Patient Journey Acceleration And Digital Innovation 6/12/2025

    From predictive AI to the European Health Data Space, industry experts discuss how digital transformation is reshaping patient care and creating new pathways for commercial success in pharmaceuticals.

  4. Insights From Pharma 2025: Elevating Patient Engagement 6/12/2025

    A significant gap exists between drug development and patient use. Industry veteran Mark Duman explains why listening to patients is the key to closing it and improving health outcomes.

  5. Insights From Pharma 2025: Leadership In Pharma – Empowering Change Through Innovative Thinking 6/12/2025

    What does it take to lead in today's evolving pharmaceutical landscape? Insights from Pharma 2025 reveal that empowering teams through trust, experimentation, and a shared purpose is key.

  6. Inclusion Of Health-Related Quality Of Life (HRQoL) And Other Patient-Reported Outcomes (PROs) In FDA Labels 6/12/2025

    With a growing emphasis on patient-centric drug development, new research examines how frequently patient-reported outcomes are actually making it onto United States Food and Drug Administration labels.

  7. Value Of Multi-Indication Immunotherapies For The Treatment Of Autoimmune Diseases In The United States 6/12/2025

    As multi-indication therapies become more common, new research questions their value. A study for ISPOR 2025 reveals a potential misalignment between the price and value of these versatile treatments.

  8. Impact Of JCA And Project Orbis On The European Revenue Potential Of An Oncology Product 6/12/2025

    Contrary to concerns about price erosion, new analysis suggests Joint Clinical Assessment and Project Orbis will likely increase European oncology product revenue by enabling faster market uptake.

  9. A Look At Elsa, The FDA's New AI Digital Assistant 6/12/2025

    The U.S. FDA recently launched its very own generative AI tool called Elsa. It's designed to assist FDA employees across various functions, from scientific reviewers to investigators.

  10. Creating A Compliant And Scalable CGT Logistics Launch Plan 6/12/2025

    As cell and gene therapies advance to commercialization, biopharma companies face immense logistical hurdles. A customized, end-to-end strategy is crucial for ensuring product integrity and market success.